Related Experiment Video
Updated: May 13, 2026
An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples
Published on: April 12, 2015
Factors affecting mesenchymal stromal cells yield from bone marrow aspiration
Jing Li1, Wilfred Hing-Sang Wong, Shing Chan
1China Oxford Centre for International Health Research, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China ; Department of Paediatrics and Adolescent Medicine, the University of Hong Kong, HKSAR, China.
For optimal mesenchymal stromal cells (MSC) yield, collect bone marrow early in harvesting. Bone marrow from donors under 55 years is suitable for MSC collection, even from leukemia patients for in-vitro expansion.
Area of Science:
- Stem cell biology
- Regenerative medicine
- Hematopoietic stem cell transplantation
Background:
- Mesenchymal stromal cells (MSCs) are crucial for tissue repair and immune modulation.
- Optimizing MSC yield from bone marrow is essential for therapeutic applications.
- Understanding factors affecting MSC collection is vital for clinical success.
Purpose of the Study:
- To identify key variables in bone marrow harvesting and donor characteristics influencing mesenchymal stromal cell (MSC) yield.
- To establish optimal conditions for obtaining high-quality MSCs for research and clinical use.
Main Methods:
- Compared MSC yield from donors of varying ages and health statuses (healthy vs. leukemia patients).
- Assessed MSC numbers based on bone marrow aspiration timing and needle type during harvesting.
- Quantified MSC colony numbers under different collection conditions.
Main Results:
- MSC yield significantly decreased with increased bone marrow volume aspirated during harvesting.
- Leukemia patients yielded significantly fewer MSCs compared to healthy donors.
- No significant difference in MSC yield was observed based on donor age (<55 years) or needle type.
Conclusions:
- Early bone marrow collection during harvesting maximizes MSC yield.
- Donors under 55 years provide suitable bone marrow for MSC sourcing.
- Autologous MSCs from leukemia patients can be expanded in vitro for potential therapeutic use.
